A New Strategy Against Treatment-Resistant Tumors

A study published in Oncogene presents an innovative strategy for the particularly complex medical challenge of destroying aggressive, treatment-resistant tumors.

The research was jointly led by early-career scientists Dr. Avital Oknin Vaisman and Dr. Deepanjan Panda from the laboratories of Prof. Amir Orian, head of the Rappaport Center for Cancer Research at the Technion – Israel Institute of Technology, and a faculty member in the Ruth and Bruce Rappaport Faculty of Medicine, and Prof. Ashraf Brik of the Schulich Faculty of Chemistry.

Aggressive cancers such as bone tumors (sarcomas) and melanoma that do not respond to molecular therapies have very limited treatment options, making them a significant unmet need in oncology. These cancer cells depend heavily on proteins called oncoproteins and have evolved ways to avoid programmed cell death. Because of this, therapies that both target oncoproteins and trigger programmed cell death may offer a promising strategy for effectively treating these cancers.

Keep reading at technologynetworks.com.